The Full Wiki

More info on Frovatriptan

Frovatriptan: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
CAS number 158930-17-7
ATC code N02CC07
PubChem 5284561
DrugBank APRD00270
Chemical data
Formula C 14H17N3O 
Mol. mass 243.304 g/mol
Synonyms 6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
Pharmacokinetic data
Bioavailability 20-30%
Metabolism Hepatic
Half life 26 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat. C: (USA)
B3: (AUS)
Legal status Prescription only
Routes Oral

Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[1]



Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. It is available as 2.5 mg tablets.

Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.

US licensing

Frovatriptan is available only by prescription in the United States, and Canada where a secondary New Drug Approval (sNDA) was filed in July 2006,[2] and which is currently pending. The FDA anticipates completing its review of this application on or before the current PDUFA (Prescription Drug User Fee Act) review date of August 19, 2007. If the sNDA is approved, Frova will be the only medication indicated in the U.S. for the short-term prevention of menstrual migraine (MM).


External links



Got something to say? Make a comment.
Your name
Your email address